Patient characteristics of the treated cohort
| Variable . | The entire population N = 596 . | OL Age, 70-80 y n = 399 . | Octo Age, >80 y n = 197 . | P value∗ . |
|---|---|---|---|---|
| Demographics | ||||
| Age at diagnosis, median (IQR), y | 77.0 (73.0-81.0) | 74.0 (72.0-77.0) | 83.0 (81.0-85.0) | <.001 |
| Male, n (%) | 355 (60) | 248 (62) | 107 (54) | .067 |
| Comorbidities, n (%) | ||||
| Diabetes | 215 (36) | 141 (35) | 74 (38) | .6 |
| Osteoporosis | 205 (34) | 123 (31) | 82 (42) | .009 |
| CKD | 108 (18) | 62 (16) | 46 (23) | .020 |
| CVA | 26 (4.4) | 14 (3.5) | 12 (6.1) | .15 |
| Hypertension | 454 (76) | 293 (73) | 161 (82) | .025 |
| Dementia | 39 (6.5) | 18 (4.5) | 21 (11) | .004 |
| CHF | 33 (5.5) | 17 (4.3) | 16 (8.1) | .053 |
| Prior malignancy | 58 (9.7) | 43 (11) | 15 (7.6) | .2 |
| CCI score, n (%) | <.001 | |||
| 3-5 | 426 (71) | 317 (79) | 109 (55) | |
| 6-7 | 130 (22) | 66 (17) | 64 (32) | |
| 8-12 | 40 (7) | 16 (4) | 24 (13) | |
| CCI score of ≥6, n (%) | 170 (29) | 82 (21) | 88 (45) | <.001 |
| MM-related laboratory results | ||||
| Anemia, n (%) | 122 (22) | 70 (18) | 52 (28) | .007 |
| Creatinine, median (IQR), mg/dL | 1.00 (0.80-1.40) | 0.90 (0.80-1.30) | 1.00 (0.80-1.40) | .026 |
| Acute renal failure, n (%) | 6 (1.1) | 5 (1.3) | 1 (0.5) | .7 |
| Calcium, median (IQR), mg/dL | 9.10 (8.70-9.50) | 9.10 (8.70-9.50) | 9.20 (8.80-9.50) | .5 |
| Albumin, median (IQR), g/dL | 3.80 (3.50-4.10) | 3.90 (3.60-4.10) | 3.70 (3.40-4.10) | .002 |
| Albumin <3.5 g/dL, n (%) | 126 (24) | 70 (20) | 56 (32) | .003 |
| Abnormal FLCR, n (%) | 223 (76) | 134 (68) | 89 (90) | <.001 |
| Treatment regimens | ||||
| Treatment period, n (%) | .5 | |||
| 2014-2018 | 241 (40) | 167 (42) | 74 (38) | |
| 2019-2022 | 275 (46) | 178 (45) | 97 (49) | |
| 2023 | 80 (13) | 54 (14) | 26 (13) | |
| Triplets/quadruplets, n (%) | 321 (54) | 229 (57) | 92 (47) | .014 |
| Regimen, n (%) | .002 | |||
| Vd | 215 (36) | 136 (34) | 79 (40) | |
| Rd | 41 (6.9) | 24 (6.0) | 17 (8.6) | |
| VRd | 167 (28) | 118 (30) | 49 (25) | |
| VCd/VMd/RMd | 70 (11.7) | 48 (12) | 22 (11.1) | |
| Dara-d | 19 (3.2) | 10 (2.5) | 9 (4.6) | |
| Dara-based triplets/quadruplets: Dara-Vd/Dara-Rd/Dara-VRd | 84 (14.1) | 63 (15.8) | 21 (10.7) | |
| Dara-based regimen, n (%) | 103 (17) | 73 (1) | 30 (15) | .4 |
| Variable . | The entire population N = 596 . | OL Age, 70-80 y n = 399 . | Octo Age, >80 y n = 197 . | P value∗ . |
|---|---|---|---|---|
| Demographics | ||||
| Age at diagnosis, median (IQR), y | 77.0 (73.0-81.0) | 74.0 (72.0-77.0) | 83.0 (81.0-85.0) | <.001 |
| Male, n (%) | 355 (60) | 248 (62) | 107 (54) | .067 |
| Comorbidities, n (%) | ||||
| Diabetes | 215 (36) | 141 (35) | 74 (38) | .6 |
| Osteoporosis | 205 (34) | 123 (31) | 82 (42) | .009 |
| CKD | 108 (18) | 62 (16) | 46 (23) | .020 |
| CVA | 26 (4.4) | 14 (3.5) | 12 (6.1) | .15 |
| Hypertension | 454 (76) | 293 (73) | 161 (82) | .025 |
| Dementia | 39 (6.5) | 18 (4.5) | 21 (11) | .004 |
| CHF | 33 (5.5) | 17 (4.3) | 16 (8.1) | .053 |
| Prior malignancy | 58 (9.7) | 43 (11) | 15 (7.6) | .2 |
| CCI score, n (%) | <.001 | |||
| 3-5 | 426 (71) | 317 (79) | 109 (55) | |
| 6-7 | 130 (22) | 66 (17) | 64 (32) | |
| 8-12 | 40 (7) | 16 (4) | 24 (13) | |
| CCI score of ≥6, n (%) | 170 (29) | 82 (21) | 88 (45) | <.001 |
| MM-related laboratory results | ||||
| Anemia, n (%) | 122 (22) | 70 (18) | 52 (28) | .007 |
| Creatinine, median (IQR), mg/dL | 1.00 (0.80-1.40) | 0.90 (0.80-1.30) | 1.00 (0.80-1.40) | .026 |
| Acute renal failure, n (%) | 6 (1.1) | 5 (1.3) | 1 (0.5) | .7 |
| Calcium, median (IQR), mg/dL | 9.10 (8.70-9.50) | 9.10 (8.70-9.50) | 9.20 (8.80-9.50) | .5 |
| Albumin, median (IQR), g/dL | 3.80 (3.50-4.10) | 3.90 (3.60-4.10) | 3.70 (3.40-4.10) | .002 |
| Albumin <3.5 g/dL, n (%) | 126 (24) | 70 (20) | 56 (32) | .003 |
| Abnormal FLCR, n (%) | 223 (76) | 134 (68) | 89 (90) | <.001 |
| Treatment regimens | ||||
| Treatment period, n (%) | .5 | |||
| 2014-2018 | 241 (40) | 167 (42) | 74 (38) | |
| 2019-2022 | 275 (46) | 178 (45) | 97 (49) | |
| 2023 | 80 (13) | 54 (14) | 26 (13) | |
| Triplets/quadruplets, n (%) | 321 (54) | 229 (57) | 92 (47) | .014 |
| Regimen, n (%) | .002 | |||
| Vd | 215 (36) | 136 (34) | 79 (40) | |
| Rd | 41 (6.9) | 24 (6.0) | 17 (8.6) | |
| VRd | 167 (28) | 118 (30) | 49 (25) | |
| VCd/VMd/RMd | 70 (11.7) | 48 (12) | 22 (11.1) | |
| Dara-d | 19 (3.2) | 10 (2.5) | 9 (4.6) | |
| Dara-based triplets/quadruplets: Dara-Vd/Dara-Rd/Dara-VRd | 84 (14.1) | 63 (15.8) | 21 (10.7) | |
| Dara-based regimen, n (%) | 103 (17) | 73 (1) | 30 (15) | .4 |
CHF, congestive heart failure; CKD, chronic kidney disease; CVA, cerebrovascular accident; RMd, lenalidomide + melphalan + dexamethasone; VCD, bortezomib + cyclophosphamide + dexamethasone; VMD, bortezomib + melphalan + dexamethasone.
Wilcoxon rank-sum test; Pearson χ2 test; Fisher exact test.